MMP2 and glioma: This modification not only enhanced systemic circulation but also preserved CTX’s binding affinity to matrix metalloproteinase-2 (MMP-2), a receptor overexpressed in gliomas, enabling precise intracellular delivery of therapeutic genes such as TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) [240].